Gene Shaw1, Richard Berg2. 1. Department of Lab-Pathology, Marshfield Clinic, Marshfield, Wisconsin shaw.gene@marshfieldclinic.org. 2. Biomedical Informatics Research Center, Marshfield Clinic Research Institute, Marshfield, Wisconsin.
Abstract
BACKGROUND: World Health Organization (WHO) 2017 diagnostic criteria for hemoglobin levels in polycythemia vera (PV) were lowered from 185 g/L to 165 g/L for men and from 165 g/L to 160 g/L for women, but these cutoffs were not designed for screening. OBJECTIVES: The primary aim of this study was to assess the value of laboratory and clinical parameters in deciding whether to further pursue a diagnosis of PV. A secondary aim was to explore the diagnostic utility of bone marrow morphology. METHODS: We evaluated clinical and laboratory parameters that may be useful when considering further diagnostic work-up, emphasizing PV vs. secondary erythrocytosis (SE). We classified 200 patients with JAK2 V617F testing using WHO criteria. RESULTS: Patients with myeloproliferative neoplasms (MPN) were rarely under age 40 and uncommonly obese (BMI ≥ 30 kg/m2). Current smoking history favored SE, and these patients rarely had a platelet count ≥ 450 × 103/uL. Laboratory parameters suggesting greater PV likelihood were: RBC > 6.8 × 106 for men or > 5.9 × 106 for women; low erythropoietin; and low MCV or low ferritin. Bone marrow morphology (available in 111 cases) was generally more cellular in PV vs. SE and assessed disease progression. CONCLUSIONS: Readily accessible clinical and laboratory data can assist in considering a PV workup, and a possible diagnostic algorithm is presented. These preliminary findings warrant larger studies to develop a more formal PV-risk scoring system with optimal cutoffs and weighting.
BACKGROUND: World Health Organization (WHO) 2017 diagnostic criteria for hemoglobin levels in polycythemia vera (PV) were lowered from 185 g/L to 165 g/L for men and from 165 g/L to 160 g/L for women, but these cutoffs were not designed for screening. OBJECTIVES: The primary aim of this study was to assess the value of laboratory and clinical parameters in deciding whether to further pursue a diagnosis of PV. A secondary aim was to explore the diagnostic utility of bone marrow morphology. METHODS: We evaluated clinical and laboratory parameters that may be useful when considering further diagnostic work-up, emphasizing PV vs. secondary erythrocytosis (SE). We classified 200 patients with JAK2 V617F testing using WHO criteria. RESULTS:Patients with myeloproliferative neoplasms (MPN) were rarely under age 40 and uncommonly obese (BMI ≥ 30 kg/m2). Current smoking history favored SE, and these patients rarely had a platelet count ≥ 450 × 103/uL. Laboratory parameters suggesting greater PV likelihood were: RBC > 6.8 × 106 for men or > 5.9 × 106 for women; low erythropoietin; and low MCV or low ferritin. Bone marrow morphology (available in 111 cases) was generally more cellular in PV vs. SE and assessed disease progression. CONCLUSIONS: Readily accessible clinical and laboratory data can assist in considering a PV workup, and a possible diagnostic algorithm is presented. These preliminary findings warrant larger studies to develop a more formal PV-risk scoring system with optimal cutoffs and weighting.
Authors: P Guglielmelli; T L Lasho; G Rotunno; J Score; C Mannarelli; A Pancrazzi; F Biamonte; A Pardanani; K Zoi; A Reiter; A Duncombe; T Fanelli; D Pietra; E Rumi; C Finke; N Gangat; R P Ketterling; R A Knudson; C A Hanson; A Bosi; A Pereira; R Manfredini; F Cervantes; G Barosi; M Cazzola; N C P Cross; A M Vannucchi; A Tefferi Journal: Leukemia Date: 2014-02-19 Impact factor: 11.528
Authors: Georg Jeryczynski; Jürgen Thiele; Bettina Gisslinger; Albert Wölfler; Martin Schalling; Andreas Gleiß; Sonja Burgstaller; Veronika Buxhofer-Ausch; Thamer Sliwa; Ernst Schlögl; Klaus Geissler; Maria-Theresa Krauth; Alexander Nader; Michael Vesely; Ingrid Simonitsch-Klupp; Leonhard Müllauer; Christine Beham-Schmid; Heinz Gisslinger Journal: Am J Hematol Date: 2017-06-09 Impact factor: 10.047
Authors: Barbara Mora; Toni Giorgino; Paola Guglielmelli; Elisa Rumi; Margherita Maffioli; Alessandro Rambaldi; Marianna Caramella; Rami Komrokji; Jason Gotlib; Jean Jacques Kiladjian; Francisco Cervantes; Timothy Devos; Francesca Palandri; Valerio De Stefano; Marco Ruggeri; Richard T Silver; Giulia Benevolo; Francesco Albano; Chiara Cavalloni; Daniela Barraco; Michele Merli; Daniela Pietra; Rosario Casalone; Tiziano Barbui; Giada Rotunno; Mario Cazzola; Alessandro Maria Vannucchi; Francesco Passamonti Journal: Haematologica Date: 2018-04-05 Impact factor: 9.941
Authors: Lambert Busque; Anna Porwit; Radmila Day; Harold J Olney; Brian Leber; Vincent Éthier; Shireen Sirhan; Linda Foltz; Jaroslav Prchal; Suzanne Kamel-Reid; Aly Karsan; Vikas Gupta Journal: Am J Clin Pathol Date: 2016-10 Impact factor: 2.493